



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/539,455	12/13/2006	Bart Van Der Burg	05-548	6860
20306	7590	05/03/2011	EXAMINER	
MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP			HIRIYANNA, KELAGINAMANE T	
300 S. WACKER DRIVE			ART UNIT	PAPER NUMBER
32ND FLOOR			1633	
CHICAGO, IL 60606				
MAIL DATE		DELIVERY MODE		
05/03/2011		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/539,455	Applicant(s) VAN DER BURG ET AL.
	Examiner KELAGINAMANE T. HIRIYANNA	Art Unit 1633

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 12 October 2010.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1 and 7-41 is/are pending in the application.
 4a) Of the above claim(s) 13-25 is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 1,7-12 and 26-41 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
 2) Notice of Draftsperson's Patent Drawing Review (PTO-942)
 3) Information Disclosure Statement(s) (PTO/SB/08)
 Paper No(s)/Mail Date _____
- 4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date _____
- 5) Notice of Informal Patent Application
 6) Other: _____

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 10/12/2010 has been entered.

Applicant's response filed on 10/12/2010 in response to office action mailed on 06/09/2010 has been acknowledged.

Claim 1 is amended.

Claims 2-6 were previously canceled.

Claims 1, 7-12 and 26-41 are pending and are examined in this office action.

Applicants are required to follow Amendment Practice under revised 37 CFR §1.121. The fax phone numbers for the organization where this application or proceeding is assigned is 571-273-8300.

Withdrawn: Claims 1, 7-12 and 26-41 rejections under 35 USC 103 (a) as being unpatentable over Evans et al., (US patent No.:5,298,429) and Quaedackers et al (2001, Endocrinology 142:1156-1166; art of record) in view of Stuelpnagel et al., (US2005/0158702 A1; art of record), Walt et al., (US 6210910B1; art of record) and Wilson et al et al (2002, Toxicological Sciences 66:69-81; art of record) for the reasons of record as set forth in the office action mailed on 06/09/2010 is withdrawn in view of the revised rejections to address the amendments to the claims..

Claim Objections

Claim 10, 15, 24, 25 and 31-34 is objected to as each recite "the pSG5 expression plasmid", this is just not proper language. It should be either just "pSG5 expression plasmid" or have a base claim which recites "a pSG5 expression plasmid".

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 35-41 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 35 recites the limitation "the ligand modifying factor" in line 1. There is insufficient antecedent basis for this limitation in the claim.

Claim 36 recites the limitation "the specific component" in line 1. There is insufficient antecedent basis for this limitation in the claim.

Claim 37 recites the limitation "the specific component" in line 1. There is insufficient antecedent basis for this limitation in the claim.

Claim 38 recites the limitation "the specific component" in line 1. There is insufficient antecedent basis for this limitation in the claim.

Claim 39 recites the limitation "at least two cell lines" in line 2. This limitation is broader than the limitation "at least three cell lines" claimed in the base claim 26 from which it depends from and that is inappropriate.

Claim 40 recites the limitation "the cellular pathway" in line 1. There is insufficient antecedent basis for this limitation in the claim.

Claim 41 recites the limitation "the cellular pathway" in line 1. There is insufficient antecedent basis for this limitation in the claim.

Applicant is advised that should claim 1 be found allowable, claim 27 will be objected to under 37 CFR 1.75 as being a substantial duplicate thereof. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 706.03(k). Claim 27 requires "the reporter gene construct comprising DNA coding for an operative hormone response element linked to a promoter and a reporter gene", however, such depends from Claim 1, which requires "the reporter gene construct comprising DNA coding for an operative hormone response element linked to a promoter and a reporter gene". Therefore, despite a slight difference in wording, Claim 27 is a substantial duplicate of Claim 1.

Applicant is advised that should claim 9 be found allowable, claim 29 will be objected to under 37 CFR 1.75 as being a substantial duplicate thereof. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 706.03(k). Claim 29 requires "the reporter gene construct comprise 3 tandem repeats....PGL3", however, such depends from Claim 27 which duplicates claim 1 (see above), where as claim 9 that is directly dependent from claim 1 requires same i.e., "the reporter gene construct comprise 3 tandem repeats....PGL3". Therefore, despite a slight difference in wording, Claim 29 is a substantial duplicate of Claim 9.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.
- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed

in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1, 7-12 and 26-41 are rejected under 102(b) as being anticipated by Quaedackers et al et al (2001, Endocrinology 142:1156-1166).

The above claims are drawn to a method for determining the presence of one or more specific ligands in a sample comprising steps of contacting the sample with an array of at least two cell lines each comprising a reporter gene construct and an expression plasmid coding for a different steroid or thyroid hormone receptor selected from a Markush group of steroid receptors, measuring the activity of reporter gene and determining by comparison the ligands in the sample.

Quaedackers teaches U2-OS cell line for expressing the hormone receptors and reporter gene and further doing reporter gene assays for detecting the steroid ligands (estrogen receptor) in samples for diagnostics (entire article; abstract; p.1157, col.2). Quaedackers specifically teach plasmids expressing specific hormone receptors under the control of hormone responsive elements present in 3 random repeats upstream of the minimal adenovirus E1B TATA promoter sequence of SEQ ID NO:2 in pGL3 plasmid and hormone receptors is introduced in the PSG5 expression plasmid in osteoblastic U2-OS cell lines that could be used as an effective cell based detection or assay of several steroid hormones (entire article; abstract). It is inherent in the skill of the artisan to place the cells in the form of an array and use them in said assays. Thus the rejected claims are within the scope of the Quaedacker's disclosure.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1, 7-12 and 26-41 are rejected under 35 USC 103 (a) as being unpatentable over Quaedackers et al (2001, Endocrinology 142:1156-1166; art of record) in view of

Stuelpnagel et al., (US2005/0158702 A1; art of record), Walt et al., (US 6210910B1; art of record) and Wilson et al et al (2002, Toxicological Sciences 66:69-81; art of record).

The above claims are drawn to a method for determining the presence of one or more specific ligands in a sample comprising steps of contacting the sample with an array of at least two cell lines each comprising a reporter gene construct and an expression plasmid coding for a different steroid or thyroid hormone receptor selected from a Markush group of steroid receptors, measuring the activity of reporter gene and determining by comparison the ligands in the sample.

Quaedackers teaches U2-OS cell line for expressing the hormone receptors and reporter gene and further doing reporter gene assays for detecting the steroid ligands (estrogen receptor) in samples for diagnostics (entire article; abstract; p.1157, col.2). Quaedackers specifically teach plasmids expressing specific hormone receptors under the control of hormone responsive elements present in 3 random repeats upstream of the minimal adenovirus E1B TATA promoter sequence of SEQ ID NO:2 in pGL3 plasmid and hormone receptors is introduced in the PSG5 expression plasmid in osteoblastic U2-OS cell lines that could be used as an effective cell based detection or assay of several steroid hormones (entire article; abstract). It is inherent in the skill of the artisan to place the cells in the form of an array and use them in said assays. Quaedakers however does not explicitly teach arraying the U2-OS cells.

Regarding the limitation of cell arrays in claims Stuelpnagel teaches a biosensor array of one or more cells or cell lines and relies on the fact that individual cells which are biologically or chemically stimulated by the ligands in the cell environment and respond by producing a change in the cell or cellular environment wherein said cell may comprise genetically engineered cells that are prokaryotic or eukaryotic, mammalian, primate etc and cell lines of any type for example osteoblast cells or chondrocytes etc (entire article; abstract; paragraphs 0030, 033-036, 0057-058). In general the cells are transformed using variety of vectors and constructs and used for functional assay of various analytes including biomolecules such as steroids etc (paragraphs 0096-0099) and in one embodiment the cell plasmids regulates the expression of marker or reporter genes such

as luciferase or encoded GFPs (paragraphs 0111-0113) depending on the ligands or their concentrations in the sample.

Similarly Walt teaches a biosensor array of individual cells or randomly mixed population of cells having unique response characteristic to or chemical or biological materials or target analytes in the cell environment and respond by producing a change in the cell or cellular environment in a detectable manner (entire article; abstract; col.5, lines 55-68 bridging col.6-9). Said cells of biosensor may comprise genetically engineered cells that are prokaryotic or eukaryotic, mammalian, primate etc and cell lines of any type for example osteoblast cells or chondrocytes etc (entire article; col.9, lines 35-54). In an embodiment the cells are transformed using variety of vectors and constructs and used for functional assay of various analytes including biomolecules such as steroids etc (col.127) and regulate the expression of marker or reporter genes such as luciferase or encoded GFPs (col.15, lines 15-42; col.28) depending on the ligands or their concentrations in the sample.

Wilson teaches the limitation of plasmids expressing specific hormone receptors and deriving a cell line that could be used as an effective cell based biosensor for detecting several steroid hormones and for screening androgen agonists and antagonists etc. wherein cells could be arrayed in 96 well plates and effectively used for screening hormonally active chemicals (entire article; abstract).

Thus it would have been obvious for one of ordinary skill in the art to array the U2-OS cells taught by Quaedaker and further array said recombinant U2-OS cells in the form of biosensor cell arrays for high throughput detection of steroid ligands and ligand modifiers as taught in Stuelpnagel, Walt or Wilson and generate live U2-OS cell based biosensor arrays for effectively detecting steroid hormones or their analogues in a sample or in the environment. One of ordinary skill in the art would have been motivated to make and use U2-Os cell arrays with hormone and related compound detection as they are more sensitive and effective in detecting said ligands in cellular environments. One of ordinary skill in the art would have reasonable expectation of success making and using biosensor of U2-OS cell arrays for detecting steroid receptor ligands and their modifiers because the art teaches that it is routine to make recombinant cells with specific receptor

and reporter for detecting ligands, toxic chemicals that affect cell pathways and specifically steroid hormones. Thus, the claimed invention was *prima facie* obvious.

Conclusion:

No claim allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner *Kelaginamane Hiriyanne Ph.D.*, whose telephone number is **(571) 272-3307**. The examiner can normally be reached Monday through Thursday from 9 AM-7PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, *Joseph Woitach Ph.D.*, may be reached at **(571) 272-0739**. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). When calling please have your application serial number or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. For all other customer support, please call the USPTO call center (UCC) at (800) 786-9199.

/ROBERT M KELLY/
Primary Examiner, Art Unit 1633